Key result
Risk models incorporating troponin and NT-proBNP predicted cardiovascular death, whereas NT-proBNP helped predict both cardiovascular and non-cardiovascular death.
Why the study?
Although heart failure patients face high cardiovascular risk, a substantial proportion die of non-cardiovascular causes, and differentiating these risks could improve clinical trial selection and tailored therapy.
Do risk models incorporating troponin and NT-proBNP accurately predict and differentiate cardiovascular from non-cardiovascular death in heart failure patients?
Cohort (n=4,047)
Do risk models incorporating troponin and NT-proBNP accurately predict and differentiate cardiovascular from non-cardiovascular death in heart failure patients?
Answers are grounded in this paper and cite their sources.
Troponin is specifically useful for predicting cardiovascular death in heart failure patients, whereas NT-proBNP predicts both cardiovascular and non-cardiovascular death, which can aid in patient selection for clinical trials.
AIMS: Heart failure (HF) patients are at high-risk of cardiovascular (CV) events, including CV death. Nonetheless, a substantial proportion of these patients die from non-CV causes. Identifying patients at higher risk for each individual event may help selecting patients for clinical trials and tailoring cardiovascular therapies. The aims of the present study are to: (i) characterize patients according to CV vs. non-CV death; (ii) develop models for the prediction of the respective events; (iii) assess the models' performance to differentiate CV from non-CV death. METHODS AND RESULTS: This study included 2309 patients with HF from the BIOSTAT-CHF (a systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure) study. Competing-risk models were used to assess the best combination of variables associated with each cause-specific death. Results were validated in an independent cohort of 1738 HF patients. The best model to predict CV death included low blood pressure, estimated glomerular filtration rate ≤ 60 mL/min, peripheral oedema, previous HF hospitalization, ischaemic HF, chronic obstructive pulmonary disease, elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP), and troponin (c-index = 0.73). The non-CV death model incorporated age > 75 years, anaemia and elevated NT-proBNP (c-index = 0.71). Both CV and non-CV death rose by quintiles of the risk scores; yet these models allowed the identification of patients in whom absolute CV death rates clearly outweigh non-CV death ones. These findings were externally replicated, but performed worse in a less severely diseased population. CONCLUSIONS: Risk models for predicting CV and non-CV death allowed the identification of patients at higher absolute risk of dying from CV causes (vs. non-CV ones). Troponin helped in predicting CV death only, whereas NT-proBNP helped in the prediction of both CV and non-CV death. These findings can be useful both for tailoring therapies and for patient selection in HF trials in order to attain CV event enrichment.
No takes yet. Share an insight, caveat, or question.
Ferreira et al. (2019) conducted a cohort in Heart failure (n=4,047). Clinical variables including Troponin and NT-proBNP was evaluated on Cardiovascular and non-cardiovascular death (c-index 0.73 for CV death; c-index 0.71 for non-CV death). Risk models incorporating troponin and NT-proBNP predicted cardiovascular death, whereas NT-proBNP helped predict both cardiovascular and non-cardiovascular death.
Synapse has enriched 10 related papers. Consider them for comparative context: